Sucampo Pharmaceuticals, Inc. Release: Phase 3 Long-Term Safety Trial Results of Lubiprostone in Patients with Irritable Bowel Syndrome with Constipation was Recently Published in Alimentary Pharmacology and Therapeutics

BETHESDA, Md.--(BUSINESS WIRE)--A recently published study in the journal Alimentary Pharmacology and Therapeutics, demonstrated the long-term safety and tolerability profiles of AMITIZA (lubiprostone) in patients with irritable bowel syndrome with constipation (IBS-C). This study, initiated by Takeda Pharmaceuticals U.S.A., Inc. and Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), was designed to determine the effects of AMITIZA in patients with IBS-C for up to 52 weeks.